KVUE · Kenvue Inc.

S&P 500 #279 · NYSE

Risiko 4/10 · Consumer health spin-off, stable but slow-growth · $19.75 ▲ 1.39%

Kennzahlen

• Price $19.75
• Market cap $37.9B
• P/E (ttm) 23.51
• Div yield 4.26%
• 52-wk range $14.02 – $22.44
• Index rank #279 / —

Wichtigste Risiken

• Volume erosion from retailer private-label competition (Revenue) — MED
• Significant debt inherited from J&J separation (Balance sheet) — MED
• Below-average organic-growth track record since spin (Multiple expansion) — MED
• GLP-1 / weight-loss drug demand dampening OTC analgesics (Self Care segment) — LOW

Fazit

Kenvue is the J&J consumer-health spin-off (Tylenol, Neutrogena, Listerine) generating reliable cash flow and a 4.5% yield but struggling to re-rate as a true growth story.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.